RxDoctor Payments Data

Koren Blankley

Family · Richmond, INNPI 1275982613

Payments from drug & device makers

$1,136in general payments, 2019–2025

Across 72 payments — averaging $15.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$368
  • Novo Nordisk$168
  • AstraZeneca$87
  • Axsome Therapeutics, Inc.$58
  • GSK$47
  • Lilly USA, LLC$36
  • plus $370 from 19 others

What the payments were for

  • Food & beverage$1,136100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,136 in reported general payments places this provider in the 70th percentile of 4,392 family providers in Indiana.

See all family providers in Indiana

Medicare billing

Part B allowed, 2024
$57,419
Medicare patients
335
Services billed
1,461

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban66$47,845
OzempicSemaglutide33$38,034
JardianceEmpagliflozin23$24,454
RybelsusSemaglutide16$23,291
MounjaroTirzepatide21$21,915
FarxigaDapagliflozin Propanediol28$21,222
EntrestoSacubitril/Valsartan13$10,915
VascepaIcosapent Ethyl14$4,349
SymbicortBudesonide/Formoterol Fumarate15$3,443
Pregabalin23$2,656
Albuterol Sulfate HfaAlbuterol Sulfate82$2,644
Varenicline Tartrate19$2,504
Omeprazole166$2,006
Gabapentin154$2,006
Lantus SolostarInsulin Glargine,hum.Rec.Anlog17$1,610

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$168$61,32649 claims
AstraZenecaFarxiga, Symbicort$87$24,66543 claims
Boehringer IngelheimJardiance$18$24,45423 claims
Lilly USA, LLCMounjaro$36$21,91521 claims
NovartisEntresto$31$10,91513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,392 family providers in Indiana.

Other family in Richmond

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →